Bupropion
- Generic Name
- Bupropion
- Brand Names
- Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18ClNO
- CAS Number
- 34911-55-2
- Unique Ingredient Identifier
- 01ZG3TPX31
- Background
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...
- Indication
Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)
- Associated Therapies
- Smoking, Cessation, Weight Loss
Maintenance Treatment for Abstinent Smokers
- First Posted Date
- 2003-07-01
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 589
- Registration Number
- NCT00063323
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1
- Conditions
- Interventions
- First Posted Date
- 2003-05-22
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 115
- Registration Number
- NCT00061087
- Locations
- 🇺🇸
Research Foundation for Mental Hygiene, Inc., New York, New York, United States
Bupropion in the Treatment of Pathological Gambling
- First Posted Date
- 2003-03-03
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 80
- Registration Number
- NCT00055393
- Locations
- 🇺🇸
Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
- Conditions
- First Posted Date
- 2002-06-18
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 20
- Registration Number
- NCT00040040
- Locations
- 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States
🇺🇸UCLA Integrated Substance Abuse Program, Los Angeles, California, United States
Combinations of Pharmacologic Smoking Cessation Treatments
- Conditions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018187
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
- Conditions
- First Posted Date
- 2001-03-15
- Last Posted Date
- 2007-05-04
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 5000
- Registration Number
- NCT00012558
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Bupropion and Weight Control for Smoking Cessation - 1
- Conditions
- Interventions
- First Posted Date
- 2000-08-10
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 349
- Registration Number
- NCT00006170
- Locations
- 🇺🇸
Western Psychiatric Institute & Clinic, Pittsburgh, Pennsylvania, United States
Cocaine Abuse and Attention Deficit Disorder - 3
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 32
- Registration Number
- NCT00000268
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Dopamine Reuptake Inhibitors of Cocaine Abuse - 1
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Yale University
- Registration Number
- NCT00000276
- Locations
- 🇺🇸
VA Connecticut Healthcare System, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.